共 66 条
[1]
Llovet JM(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[2]
Yeo W(2005)A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 1532-1538
[3]
Cheng A-L(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
[4]
Cheng A-L(2013)Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial J Clin Oncol 31 4067-4075
[5]
Johnson PJ(2013)Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J Clin Oncol 31 3517-3524
[6]
Kudo M(2015)A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE) J Clin Oncol 33 4018-66
[7]
Bruix J(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 389 56-2502
[8]
El-Khoueiry AB(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-1173
[9]
Kudo M(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 391 1163-1905
[10]
Finn RS(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 382 1894-124